Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $25,387.30 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 1,270 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $19.99, for a total transaction of $25,387.30. Following the completion of the transaction, the director now directly owns 137,155 shares of the company’s stock, valued at approximately $2,741,728.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock opened at $17.30 on Thursday. The business has a 50 day moving average of $16.98 and a 200-day moving average of $14.31. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $26.00. The company has a market capitalization of $712.76 million, a P/E ratio of -7.90 and a beta of 1.06.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.09. Equities analysts anticipate that Enliven Therapeutics, Inc. will post -2.16 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Mizuho initiated coverage on Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective for the company.

Institutional Trading of Enliven Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AJOVista LLC acquired a new stake in Enliven Therapeutics during the 4th quarter valued at approximately $28,000. Tower Research Capital LLC TRC acquired a new stake in Enliven Therapeutics during the 1st quarter valued at approximately $36,000. Ameritas Investment Partners Inc. acquired a new stake in Enliven Therapeutics during the 2nd quarter valued at approximately $39,000. Royal Bank of Canada increased its position in Enliven Therapeutics by 532.7% during the 2nd quarter. Royal Bank of Canada now owns 3,075 shares of the company’s stock valued at $63,000 after purchasing an additional 2,589 shares during the period. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Enliven Therapeutics during the 4th quarter valued at approximately $66,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.